Is LB Pharmaceuticals Inc Common Stock a good investment? LB Pharmaceuticals Inc Common Stock (LBRX) is currently trading at 43.01 USD. Market analysts have a consensus price target of 58.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: LB Pharmaceuticals Inc Common Stock is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is -5.73.
No, it does not currently pay a dividend.
LB Pharmaceuticals Inc Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of -1.12.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Community Discussion